The Food and Drug Administration yesterday released new draft guidance for labeling medications that carry the risk of abuse or dependence, including but not limited to opioids, and simplifying labels with complicated usage instructions. Changes for potentially habit-forming drugs include defining terminology, such as abuse, misuse, addiction, physical dependence and tolerance, to avoid misinterpretation on labels. According to the guidance, opioid-specific labeling should include information about how health care professionals can safely decrease the dosage in physically dependent patients, with a goal of finding the balance in pain management and reduced use. For medications with detailed instructions for use, the FDA recommends patient-friendly visual guides that are consistent in content and format.

Related News Articles

Headline
The National Academies of Sciences Engineering, and Medicine yesterday released recommendations for improving outcomes and metrics associated with four grant…
Headline
The Centers for Medicare & Medicaid Services recently announced a six-month delay in implementation of its Innovation Center Maternal Opioid Misuse (MOM)…
Headline
Mallinckrodt Pharmaceuticals today announced an agreement in principle on a settlement to resolve all opioid-related claims against the company in…
Headline
Public and private entities can apply for $1 million grants for a three-year period to enhance or expand opioid and other substance use disorder services in…
Headline
Rep. Vicky Hartzler, R-Mo., House Energy and Commerce Committee Ranking Member Greg Walden, R-Ore., and other Republicans on the committee last week asked the…
Headline
The House Energy and Commerce Subcommittee on Oversight and Investigations today held a hearing to highlight how federal funds have helped states combat…